Summer 2026 - Undergraduate Translational Development Internship at Bristol-Myers Squibb

Winter Garden, Florida, United States

Apply Now

Not SpecifiedCompensation

InternshipExperience Level

InternshipJob Type

UnknownVisa

Pharmaceuticals, BiotechnologyIndustries

Requirements

Current student majoring in a field related to biomedical sciences (cancer biology, cellular immunology, molecular oncology, genomics)
Interpersonal and collaboration skills, including the willingness and ability to foster working relationships with a range of stakeholders and work independently
Flexible to changing priorities
Prior experience in analyzing genomic and epigenomic data (WGS/WES, Methylome, Transcriptome and familiar with ctDNA) is preferred
Available full time (40hrs/week) throughout the internship period (early June through mid-August 2026)
Authorized to work in the US both at the time of hire and for the duration of employment (no immigration or visa sponsorship available)

Responsibilities

Actively contribute to experimental design and execution of a translational project aligned with GI/GU Disease Team, Translational Development
Participate in BMS student internship requirements
Conduct literature/data review to understand project context, impact and timely communication of data
Present internship project to the Translational Development group at the conclusion of the internship

Skills

Bioinformatics

Epigenetics

Methylation Analysis

Colorectal Cancer

ctDNA

Biomarkers

Translational Research

Tumor Biology

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free